Molecular Templates, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity - Additional Information (Detail)

Stockholders' Equity - Additional Information (Detail) - USD ($)							1 Months Ended	12 Months Ended
	Nov. 25, 2019	Sep. 25, 2018	Feb. 28, 2018	Feb. 27, 2018	Aug. 01, 2017	Jun. 23, 2017	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
Class Of Warrant Or Right [Line Items]
Valuation of equity classified warrants recorded in additional paid-n capital									$ 1,522,000
Preferred stock, par value								$ 0.001	$ 0.001
Term Loan Facility \| Perceptive Credit Facility
Class Of Warrant Or Right [Line Items]
Warrant exercisable period				7 years
Common stock exercise price				$ 9.5792
Number of shares to be issued upon exercise of warrant				190,000
Series A Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Shares issued under public offering	250
Shares issued, price per share	$ 8,000
Preferred stock, conversion basis	Each share of Series A Preferred Stock is convertible to 1,000 shares of Common Stock, provided that the holder of Series A Preferred Stock will be prohibited from converting the Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding.
Number of preferred stock converted into common stock	1,000
Minimum holding percentage of common stock issued and outstanding upon conversion	9.99%
Preferred stock, par value	$ 0.001
Preferred Stock , voting rights description								The Series A Preferred Stock has no voting rights, except as required by law and except that the consent of the Series A Preferred Stockholders will be required to amend the terms of the Series A Preferred Stock.
Preferred stock beneficial conversion feature intrinsic value	$ 700,000
Common Stock
Class Of Warrant Or Right [Line Items]
Valuation of equity classified warrants recorded in additional paid-n capital									$ 0
Shares issued under public offering								6,900,000	9,430,000
Common Stock \| Term Loan Facility \| Perceptive Credit Facility
Class Of Warrant Or Right [Line Items]
Warrant exercisable period			7 years
Common stock exercise price			$ 9.58
Valuation of equity classified warrants recorded in additional paid-n capital			$ 1,500,000
Expected dividend rate			0.00%
Expected volatility			105.00%
Risk free interest rate			2.80%
Expected term			7 years
Number of shares to be issued upon exercise of warrant			190,000
Wedbush Agreement
Class Of Warrant Or Right [Line Items]
Valuation of equity classified warrants recorded in additional paid-n capital							$ 400,000
Expected dividend rate							0.00%
Expected volatility							108.00%
Risk free interest rate							2.30%
Expected term							7 years
Takeda Pharmaceuticals Inc
Class Of Warrant Or Right [Line Items]
Aggregate purchase price						$ 20,000,000
Each unit of shares transaction of common stock						2,922,993
Purchase price per share						$ 6.8423
Vertex Pharmaceuticals Inc
Class Of Warrant Or Right [Line Items]
Aggregate purchase price						$ 15,000,000
Each unit of shares transaction of common stock						1,666,666
Purchase price per share						$ 9.00
Private Placement \| Common Stock
Class Of Warrant Or Right [Line Items]
Valuation of equity classified warrants recorded in additional paid-n capital					$ 16,300,000
Expected dividend rate					0.00%
Expected volatility					147.00%
Risk free interest rate					2.07%
Expected term					7 years
Shares issued under public offering								1,666,666
Private Placement \| Longitude Venture Partners III, L.P.
Class Of Warrant Or Right [Line Items]
Number of aggregate units sold					5,793,063
Aggregate purchase price					$ 40,000,000
Each unit of shares transaction of common stock					1
Warrants to purchase shares of common stock					0.5
Sale of units, description and its composition								the Company sold an aggregate of 5,793,063 units (the “Units”) having an aggregate purchase price of $40.0 million (“PIPE Financing”), each such Unit consisting of (i) one (1) share (the “Shares”) of our common stock and (ii) a warrant (the “Private Placement Warrants”) to purchase 0.5 shares of our common stock (the “Private Placement”).
Purchase price per unit					$ 6.9048
Warrant exercisable period					7 years
Common stock exercise price					$ 6.8423
Private Placement \| Longitude Venture Partners III, L.P. \| Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock								2,896,528
Private Placement \| Wedbush Agreement \| Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock							57,930	57,930
Warrant exercisable period							7 years
Common stock exercise price							$ 6.8423
Underwritten Public Offering
Class Of Warrant Or Right [Line Items]
Shares issued under public offering		9,430,000
Shares issued, price per share		$ 5.50
Proceeds from public offering		$ 48,100,000
Over Allotment Option
Class Of Warrant Or Right [Line Items]
Shares issued under public offering	900,000	1,230,000
2019 Underwritten Public Offering
Class Of Warrant Or Right [Line Items]
Shares issued under public offering	6,900,000
Shares issued, price per share	$ 8.00
Proceeds from public offering	$ 53,400,000